{'fraction_non_alphanumeric': 0.03734439834024896, 'fraction_numerical': 0.017427385892116183, 'mean_word_length': 5.184615384615385, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer.

Chemokine-like factor super family (CKLFSF) is a gene family reported in 2003. In humans, the family is composed of nine members, namely Chemokine-like factor (CKLF) and CKLF-like MARVEL transmembrane domain-containing member 1(cid:0)8 (CMTM1–8) [1]. Genes in the CMTM family have different spliceosomes, which code for MAL-related proteins for vesicle trafficking and membrane link domain (MARVEL). Studies have shown that molecules containing this domain play important physiological and pathological roles in protein transport [2]. CMTM family plays an important role in the immune system and occurrence of tumors. Among them, CMTM3 and CMTM7 have functional characteristics of tumor suppressors, which are co-located with early endosomal marker Rab5, regulating the traffic and stability of membrane molecules, such as EGFR, VE-cadherin and BCR. Australian and Dutch researchers found that CMTM6 is the only gene that can regulate PD-L1 expression in the absence of IFN γ . CMTM6 inhibits PD-L1 ubiquitination and extends its half-life, avoiding lysosome-mediated